Figure 4 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

<p>cfDNA fragmentation and mutations in plasma of patients with HGGs. <b>A,</b> The table shows the number and percentage of patients analyzed and detected with the ARTEMIS–DELFI assay, the tumor-guided mutational panel approach, or both. <b>B,</b> Histogram representation of the sensitivity of HGG detection by the mutation panel or the ARTEMIS–DELFI approach. The score threshold corresponding to 90% specificity is applied to determine the samples detected by ARTEMIS–DELFI approach. The analytical specificity of the tumor-informed mutation panel assay is 99.9%. <b>C,</b> Fragment length distribution of tumor-specific mutant fragments vs. fragments with no mutations, germline mutations or known clonal hematopoiesis of indeterminate potential (CHIP) mutations. Tumor-specific mutations are residing in shorter fragments than wild-type (WT) or nontumor mutant fragments (median length of 146 bp vs. 167 bp, Wilcoxon <i>P</i> < 0.0001).</p>